Kirsten McAulay

Kirsten is a medicinal chemist and the team leader for the AC-BI collaboration; a collaboration between the Centre for Targeted Protein Degradation and Boehringer Ingelheim. Her team focusses on the development of novel PROTACs for the targeted degradation of proteins implicated in oncological disease. Prior to her current role, she held positions at Cancer Research Horizons and AstraZeneca where she worked on small molecule and covalent inhibitor projects.